Introduction {#s1}
============

As the core component of cell nucleus, DNA suffers from various damaging agents such as chemicals, radiations and some endogenous elements. Under these damages, single strand breaks (SSBs) occur. Subsequently, unrepaired SSBs lead to double strand breaks (DSBs) during the S phase of cell cycle [@pone.0091202-Khanna1]. It has been demonstrated that accumulation of unrepaired DSBs can cause cell death and initiate malignancies [@pone.0091202-Lengauer1], which highlights the disorder of DNA repair as the key role in tumorigenesis.

There are several mechanisms repairing DSBs, among which homologous recombination repair (HRR) is the key pathway functioning in the S phase of somatic mammalian cell cycle [@pone.0091202-Lengauer1]. Defective HRR has been reported to be closely related to human cancers [@pone.0091202-Cerbinskaite1]. During the HRR process, a sister chromatid is provided as a template and the homologous sequence of DNA is aligned. A wide range of crucial molecules have been identified to participate in the HRR process [@pone.0091202-West1].Recently, researches have revealed that RAD51 paralogs (RAD51B, RAD51C, RAD51D, XRCC2, XRCC3) could serve as central proteins during the HRR process [@pone.0091202-Suwaki1].

Coded by X-ray repair cross complementing group 2(*XRCC2*) gene, the XRCC2 protein, together with other proteins, RAD51L3 for example [@pone.0091202-Braybrooke1], forms a complex which plays a critical role in chromosome segregation and apoptotic response to DSBs [@pone.0091202-Griffin1]. Johnson et al. observed over 100-folds of HRR reduction in the XRCC2 deficient hamster cells compared with the parental cells [@pone.0091202-Johnson1], which confirmed the essential function of the XRCC2 protein for the HRR process. Studies have found that single nucleotide polymorphisms (SNPs) in the DNA repair gene might modify DNA repair capacity and subsequently influence susceptibility of cancer [@pone.0091202-Clarkson1]. Recently, studies have focused on the influence of SNPs in the *XRCC2* gene on genomic instability and tumorigenesis. However, the exact function of SNPs in the *XRCC2* gene in response to different DNA damaging agents still remained unclear. There is a G to A polymorphism located in exon 3 of the *XRCC2* gene resulting in a substitution of histidine (His) for arginine (Arg). Known as Arg188His (R188H, rs3218536), this polymorphism has been widely investigated to explore its potential impact on cancer susceptibility.

A previous meta-analysis reported no significant association between *XRCC2* Arg188His polymorphism and breast cancer risk, whereas only one specific cancer type included led to its limitation and the unexplained heterogeneity might reduce the validity of the conclusion [@pone.0091202-Yu1]. It was widely reported that a single SNP was related to multiple human cancers, which revealed critical common characteristics among mechanisms of different types of cancer [@pone.0091202-Zhang1], [@pone.0091202-Wang1]. Recently, a large number of studies have attempted to identify the association between this polymorphism and other human cancers such as ovarian cancer [@pone.0091202-Auranen1], thyroid cancer [@pone.0091202-GarciaQuispes1], and colorectal cancer [@pone.0091202-Curtin1]. However, results of these studies still remain inconsistent rather than conclusive.

As to other SNPs within the *XRCC2* gene such as rs718282, rs3218373, and rs6464268, meta-analysis could not be performed due to insufficient published studies. Given the essential role of *XRCC2* gene in tumorigenesis, and a relatively small sample size for a single study, we conducted a meta-analysis including all published literature to evaluate the impact of the *XRCC2* Arg188His polymorphism on susceptibility of all available types of cancer.

Materials and Methods {#s2}
=====================

Search strategy {#s2a}
---------------

A systematic search with no limits was performed in PubMed and Embase databases to identify all the studies on the association between *XRCC2* Arg188His polymorphism and cancer risk (last search updated on Sep. 7, 2013). The following search terms were adopted jointly: 'polymorphism or variant or mutation', 'cancer or carcinoma' and 'XRCC2'. In addition, cited references of eligible studies and relevant articles were hand-searched as appropriate.

Inclusion and exclusion criteria {#s2b}
--------------------------------

Studies consistent with the following criteria were included in our meta-analysis: (1) assessing the association between the *XRCC2* Arg188His polymorphism and risk for cancer; (2) case-control studies; (3) sufficient data (a detailed number of genotypes including Arg/Arg, Arg/His and His/His in both the case and the control group); (4) English articles. Correspondingly, studies in accord with any of the following items were excluded: (1) reviews and abstracts; (2) departure from Hardy--Weinberg equilibrium (HWE) detected in controls. Studies recruiting patients during overlapping time in the same hospital were regarded as repeating data; only studies with larger numbers of patients and controls were included.

Data extraction {#s2c}
---------------

According to the inclusion criteria above, two investigators (YZH and YCZ) extracted information independently from all eligible studies. Disagreements were resolved by discussion. If consensus could not be reached, we consulted a third reviewer (ZQW). Items extracted from all included studies were listed as follows: first author, year of publication, country of origin, ethnicity, cancer type, source of control groups (population-based or hospital-based), number of cases and controls, genotyping methods, selection criteria for controls ,minor allele frequency (MAF) and fitness of HWE in controls. For articles including separate case-control studies for different study centers, different ethnic groups or cancer types, data were collected separately whenever possible due to the potential between-study heterogeneity.

Statistical analysis {#s2d}
--------------------

Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were used as the measure of effect to evaluate the strength of association between the *XRCC2* Arg188His polymorphism and cancer susceptibility. Data were pooled using the Mantel-Haenszel method (P\<0.05 was considered as statistically significant). For this polymorphism, the dominant model (Dom:His/His + Arg/His vs. Arg/Arg), recessive model (Rec:His/His vs. Arg/His +Arg/Arg) and additive model (Add: comparison of weights for His/His as '2', Arg/His as '1' and Arg/Arg as '0') were chosen to calculate the pooled ORs.

In view of the potential heterogeneity among studies with different cancer types and various ethnicities, the random-effects model (the DerSimonian and Laird method) was adopted. Heterogeneity among eligible studies was assessed by Cochran\'s Q test. The P-value\<0.1 indicated significant heterogeneity according to the previous study [@pone.0091202-Zhang2]. We conducted stratified analyses by variables such as cancer types, and ethnicity. Notably, if significant heterogeneity was observed after stratified analysis, a meta-regression analysis was performed to explore the potential origin of heterogeneity. By sequentially excluding every single study, we conducted sensitivity analysis to identify stability of the results and check whether any single study contributed to the heterogeneity significantly.

Considering that enough studies should be included in order to observe the variation trend of the ORs effectively, we performed cumulative meta-analysis as evidence accumulated by time when 10 or more studies were included. Hardy-Weinberg equilibrium (HWE) was assessed by Pearson\'s χ2 test, and P\<0.05 was regarded as departure from HWE. We checked the symmetry of Begg\'s funnel plot and the results of Egger\'s test to assess the publication bias. All of the statistical analyses were conducted by STATA (version 12.0; StataCorp,College Station, Tex).

Results {#s3}
=======

Identification and characteristics of eligible studies {#s3a}
------------------------------------------------------

After initial search with duplicates discarded, a total of 225 records of publications were yielded. Following the predefined inclusion and exclusion criteria, eventually 26 articles with 45 case-control studies were included in this meta-analysis (details in [Fig.1](#pone-0091202-g001){ref-type="fig"}).
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After comprehensive screening, 26 publications were finally included.](pone.0091202.g001){#pone-0091202-g001}

The basic characteristics of eligible studies were listed in [Table.1](#pone-0091202-t001){ref-type="table"}. Among these eligible studies, there were 14 case-control studies from 7 articles that investigated association between the Arg188His polymorphism and breast cancer risk [@pone.0091202-Brooks1]--[@pone.0091202-Webb1], and 9 studies from 6 articles focused on gynecological cancer such as ovarian cancer [@pone.0091202-Auranen1], [@pone.0091202-Webb1], [@pone.0091202-Beesley1],endometrial cancer [@pone.0091202-Han2], [@pone.0091202-RomanowiczMakowska2] and cervical cancer [@pone.0091202-Perez1]. Moreover, a wide range of other cancer types were covered by studies including thyroid [@pone.0091202-GarciaQuispes1], [@pone.0091202-Bastos1], [@pone.0091202-Fayaz1], pancreatic [@pone.0091202-Jiao1], colorectal [@pone.0091202-Curtin1], [@pone.0091202-Krupa1], bladder [@pone.0091202-Matullo1], [@pone.0091202-Figueroa1], brain [@pone.0091202-Rajaraman1], skin [@pone.0091202-Han3], upper aerodigestive tract (UADT) [@pone.0091202-Benhamou1], [@pone.0091202-RomanowiczMakowska3] and lung [@pone.0091202-Hung1], [@pone.0091202-Zienolddiny1] cancer. As to ethnicity, most of the eligible studies were performed in Caucasians, except for 1 study in African Americans [@pone.0091202-Millikan1] ([Table 1](#pone-0091202-t001){ref-type="table"}). Furthermore, 3 studies reported association in both smokers and non-smokers [@pone.0091202-Jiao1], [@pone.0091202-Matullo1], [@pone.0091202-RomanowiczMakowska3]. As shown in [Table 1](#pone-0091202-t001){ref-type="table"}, the source of controls was divided into hospital-based and population-based, and different selecting criteria for the control group were adopted. The distributions of genotypes for all genetic models were summarized in [Table 2](#pone-0091202-t002){ref-type="table"}.

10.1371/journal.pone.0091202.t001

###### Baseline characteristics of eligible case-control studies.

![](pone.0091202.t001){#pone-0091202-t001-1}

  First Author                                                      N[\*](#nt101){ref-type="table-fn"}   Year        Cancer Type          Country       Ethnicity       Source of Control   Cases/Controls   Genotyping Method   Selection criteria for controls
  ---------------------------------------------------------------- ------------------------------------ ------ ------------------------ ----------- ------------------ ------------------- ---------------- ------------------- ---------------------------------
  Brooks [@pone.0091202-Brooks1]                                                                         2008       Breast cancer           US            Mixed                NA              602/602           PCR-RFLP                      Age
  García-Closas [@pone.0091202-GarciaClosas1]                                                            2006       Breast cancer         Poland        Caucasian              PB             1981/2280             NA                         Age
  Han [@pone.0091202-Han1]                                                                               2004       Breast cancer           US            Mixed                PB              952/1237      TaqMan/ABI PRISM                  Age
  Millikan [@pone.0091202-Millikan1]                                                1                    2005       Breast cancer           US       African American          PB              765/678            TaqMan                  Age/Ethnicity
  Millikan [@pone.0091202-Millikan1]                                                2                    2005       Breast cancer           US          Caucasian              PB             1268/1134           TaqMan                  Age/Ethnicity
  Pharoah [@pone.0091202-Pharoah1]                                                  1                    2006       Breast cancer           UK          Caucasian              HB              254/194           PCR-RFLP                      NA
  Pharoah [@pone.0091202-Pharoah1]                                                  2                    2006       Breast cancer           UK          Caucasian              PB              585/598           PCR-RFLP                      NA
  Pharoah [@pone.0091202-Pharoah1]                                                  3                    2006       Breast cancer           UK          Caucasian              HB              863/845            TaqMan                       NA
  Pharoah [@pone.0091202-Pharoah1]                                                  4                    2006       Breast cancer           UK          Caucasian              PB             1865/1402           TaqMan                       Age
  Pharoah [@pone.0091202-Pharoah1]                                                  5                    2006       Breast cancer           UK          Caucasian              PB             4364/5246           TaqMan                     Region
  Pharoah [@pone.0091202-Pharoah1]                                                  6                    2006       Breast cancer           UK          Caucasian              PB              973/968            TaqMan                       NA
  Pharoah [@pone.0091202-Pharoah1]                                                  7                    2006       Breast cancer           UK            Mixed                HB              712/1046           TaqMan                       NA
  Romanowicz-Makowska [@pone.0091202-RomanowiczMakowska1]                                                2012       Breast cancer         Poland        Caucasian              NA              790/798           PCR-RFLP                      NA
  Webb [@pone.0091202-Webb1]                                                        1                    2005       Breast cancer        Australia   Caucasian/Mixed           PB              1447/783          ABI PRISM                     Age
  Webb [@pone.0091202-Webb1] [\*\*](#nt102){ref-type="table-fn"}                    2                    2005       Breast cancer        Australia      Caucasian              PB              1298/658          ABI PRISM                     Age
  Auranen [@pone.0091202-Auranen1]                                                  1                    2005       Ovarian cancer          UK          Caucasian              PB              729/842       TaqMan/ABI PRISM                Region
  Auranen [@pone.0091202-Auranen1]                                                  2                    2005       Ovarian cancer        Denmark       Caucasian              PB              269/561       TaqMan/ABI PRISM                Region
  Auranen [@pone.0091202-Auranen1]                                                  3                    2005       Ovarian cancer          US          Caucasian              PB              315/404       TaqMan/ABI PRISM             Age/Ethnicity
  Auranen [@pone.0091202-Auranen1]                                                  4                    2005       Ovarian cancer          UK          Caucasian              PB              275/1811      TaqMan/ABI PRISM                  NA
  Beesley [@pone.0091202-Beesley1]                                                                       2007       Ovarian cancer       Australia      Caucasian              PB              923/818         MALDI-TOF-MS                    NA
  Webb [@pone.0091202-Webb1]                                                        3                    2005       Ovarian cancer       Australia   Caucasian/Mixed           PB              524/1118          ABI PRISM                     Age
  Webb [@pone.0091202-Webb1] [\*\*](#nt102){ref-type="table-fn"}                    4                    2005       Ovarian cancer       Australia      Caucasian              PB              430/950           ABI PRISM                     Age
  Han [@pone.0091202-Han2]                                                                               2004     Endometrial cancer        US            Mixed                NA              217/659       TaqMan/ABI PRISM                  Age
  Romanowicz-Makowska [@pone.0091202-RomanowiczMakowska2]                                                2012     Endometrial cancer      Poland        Caucasian              NA              230/236           PCR-RFLP                      NA
  Pérez [@pone.0091202-Perez1]                                                                           2013      Cervical cancer       Argentina      Caucasian              PB              117/205            PCR EIA                      NA
  Rajaraman [@pone.0091202-Rajaraman1]                                              1                    2010           Glioma              US            Mixed                HB              342/468            TaqMan           Age/Ethnicity/Sex/Hospital
  Rajaraman [@pone.0091202-Rajaraman1]                                              2                    2010         Meningioma            US            Mixed                HB              121/468            TaqMan           Age/Ethnicity/Sex/Hospital
  Rajaraman [@pone.0091202-Rajaraman1]                                              3                    2010      Acoustic neuroma         US            Mixed                HB               65/468            TaqMan           Age/Ethnicity/Sex/Hospital
  Han [@pone.0091202-Han3]                                                          1                    2004          Melanoma             US            Mixed                PB              214/864       TaqMan/ABI PRISM             Age/Ethnicity
  Han [@pone.0091202-Han3]                                                          2                    2004    Squamous cell cancer       US            Mixed                PB              284/864       TaqMan/ABI PRISM             Age/Ethnicity
  Han [@pone.0091202-Han3]                                                          3                    2004     Basal cell cancer         US            Mixed                PB              298/864       TaqMan/ABI PRISM             Age/Ethnicity
  Benhamou [@pone.0091202-Benhamou1]                                                1                    2004   Oral/Pharyngeal cancer    France        Caucasian              HB              119/165           PCR-RFLP               Age/Sex/Hospital
  Benhamou [@pone.0091202-Benhamou1]                                                2                    2004      Laryngeal cancer       France        Caucasian              HB              127/165           PCR-RFLP               Age/Sex/Hospital
  Romanowicz-Makowska [@pone.0091202-RomanowiczMakowska3]                                                2012      Larygeal cancer        Poland        Caucasian              NA              253/253           PCR-RFLP                      NA
  Jiao [@pone.0091202-Jiao1]                                                        1                    2008     Pancreatic Cancer         US          Caucasian              HB              386/418           PCR-RFLP                      NA
  Jiao [@pone.0091202-Jiao1]                                                        2                    2008     Pancreatic Cancer         US          Caucasian              HB               24/19            PCR-RFLP                      NA
  Curtin [@pone.0091202-Curtin1]                                                                         2009     Colorectal cancer         US            Mixed                PB             1209/1380           SNPlex                     Age/Sex
  Krupa [@pone.0091202-Krupa1]                                                                           2011     Colorectal cancer       Poland        Caucasian              HB              100/100           PCR-RFLP                    Sex/Age
  Figueroa [@pone.0091202-Figueroa1]                                                                     2007       Bladder cancer         Spain        Caucasian              HB             1138/1129           TaqMan            Age/Sex/Ethnicity/Region
  Matullo [@pone.0091202-Matullo1]                                                                       2005       Bladder cancer         Italy        Caucasian              HB              156/109           PCR-RFLP                  Age/Region
  Hung [@pone.0091202-Hung1]                                                                             2008        Lung cancer          France          Mixed               HB/PB           2417/3812       TaqMan/PCR-RFLP                  NA
  Zienolddiny [@pone.0091202-Zienolddiny1]                                                               2005        Lung cancer          Norway        Caucasian              PB              312/293             APEX                     Age/Smoke
  Bastos [@pone.0091202-Bastos1]                                                                         2009       Thyroid cancer       Portugal       Caucasian              PB              109/217           PCR-RFLP                      NA
  Fayaz [@pone.0091202-Fayaz1]                                                                           2012       Thyroid cancer         Iran         Caucasian              PB               50/50             PCR-HRM                      NA
  García-Quispes [@pone.0091202-GarciaQuispes1]                                                          2011       Thyroid cancer         Spain        Caucasian              PB              397/477             iPLEX                       NA

\* Number °f case-control studies separately reported by articles.

^\*\*^Studies included only in the subgroup meta-analysis of ethnicity.

PB: population-based; HB: hospital-based; NA: not available; PCR: polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; MALDI-TOF-MS: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; PCR-HRM: polymerase chain reaction -high resolution melting; APEX: arrayed primer extension; PCR EIA: Polymerase Chain Reaction-Enzyme Immunoassay.

10.1371/journal.pone.0091202.t002

###### Genotype distribution of *XRCC2* Arg188His polymorphism.

![](pone.0091202.t002){#pone-0091202-t002-2}

  First Author                                                      N[\*](#nt104){ref-type="table-fn"}   Year        Cancer Type         Case   Control   HWE   MAF in controls                                  
  ---------------------------------------------------------------- ------------------------------------ ------ ------------------------ ------ --------- ----- ----------------- ------ ------ ----- ----- ----- ------
  Brooks [@pone.0091202-Brooks1]                                                                         2008       Breast cancer        602      515     83           4          602    519    78     5    Yes   0.07
  García-Closas [@pone.0091202-GarciaClosas1]                                                            2006       Breast cancer        1981    1763     212          6          2280   1983   281   16    Yes   0.07
  Han [@pone.0091202-Han1]                                                                               2004       Breast cancer        952      811     134          7          1237   1066   165    6    Yes   0.07
  Millikan [@pone.0091202-Millikan1]                                                1                    2005       Breast cancer        765      744     21           0          678    653    25     0    Yes   0.02
  Millikan [@pone.0091202-Millikan1]                                                2                    2005       Breast cancer        1268    1084     176          8          1134   982    145    7    Yes   0.07
  Pharoah [@pone.0091202-Pharoah1]                                                  1                    2006       Breast cancer        254      222     31           1          194    161    32     1    Yes   0.09
  Pharoah [@pone.0091202-Pharoah1]                                                  2                    2006       Breast cancer        585      491     91           3          598    507    84     7    Yes   0.08
  Pharoah [@pone.0091202-Pharoah1]                                                  3                    2006       Breast cancer        863      695     152         16          845    698    136   11    Yes   0.09
  Pharoah [@pone.0091202-Pharoah1]                                                  4                    2006       Breast cancer        1865    1662     198          5          1402   1177   214   11    Yes   0.08
  Pharoah [@pone.0091202-Pharoah1]                                                  5                    2006       Breast cancer        4363    3698     633         32          5246   4385   824   37    Yes   0.09
  Pharoah [@pone.0091202-Pharoah1]                                                  6                    2006       Breast cancer        973      818     145         10          968    807    155    6    Yes   0.09
  Pharoah [@pone.0091202-Pharoah1]                                                  7                    2006       Breast cancer        712      587     122          3          1046   882    161    3    Yes   0.08
  Romanowicz-Makowska [@pone.0091202-RomanowiczMakowska1]                                                2012       Breast cancer        790      212     374         204         798    202    406   190   Yes   0.49
  Webb [@pone.0091202-Webb1]                                                        1                    2005       Breast cancer        1447    1251     187          9          783    675    101    7    Yes   0.07
  Webb [@pone.0091202-Webb1] [\*\*](#nt105){ref-type="table-fn"}                    2                    2005       Breast cancer        1298    1113     177          8          658    562    90     6    Yes   0.08
  Auranen [@pone.0091202-Auranen1]                                                  1                    2005       Ovarian cancer       729      629     98           2          842    704    129    9    Yes   0.09
  Auranen [@pone.0091202-Auranen1]                                                  2                    2005       Ovarian cancer       269      238     31           0          561    484    75     2    Yes   0.07
  Auranen [@pone.0091202-Auranen1]                                                  3                    2005       Ovarian cancer       315      260     54           1          404    331    68     5    Yes   0.10
  Auranen [@pone.0091202-Auranen1]                                                  4                    2005       Ovarian cancer       275      251     23           1          1811   1538   267    6    Yes   0.08
  Beesley [@pone.0091202-Beesley1]                                                                       2007       Ovarian cancer       923      799     117          7          818    696    115    7    Yes   0.08
  Webb [@pone.0091202-Webb1]                                                        3                    2005       Ovarian cancer       524      451     68           5          1118   952    156   10    Yes   0.08
  Webb [@pone.0091202-Webb1] [\*\*](#nt105){ref-type="table-fn"}                    4                    2005       Ovarian cancer       430      364     63           3          950    802    140    8    Yes   0.08
  Han [@pone.0091202-Han2]                                                                               2004     Endometrial cancer     217      183     32           2          659    557    99     3    Yes   0.08
  Romanowicz-Makowska [@pone.0091202-RomanowiczMakowska2]                                                2012     Endometrial cancer     230      61      111         58          236     57    126   53    Yes   0.49
  Pérez [@pone.0091202-Perez1]                                                                           2013      Cervical cancer       117      106     11           0          205    165    40     0    Yes   0.10
  Rajaraman [@pone.0091202-Rajaraman1]                                              1                    2010           Glioma           342      285     56           1          468    395    70     3    Yes   0.08
  Rajaraman [@pone.0091202-Rajaraman1]                                              2                    2010         Meningioma         121      106     14           1          468    395    70     3    Yes   0.08
  Rajaraman [@pone.0091202-Rajaraman1]                                              3                    2010      Acoustic neuroma       65      57       8           0          468    395    70     3    Yes   0.08
  Han [@pone.0091202-Han3]                                                          1                    2004          Melanoma          214      181     31           2          864    730    127    7    Yes   0.08
  Han [@pone.0091202-Han3]                                                          2                    2004    Squamous cell cancer    284      239     42           3          864    730    127    7    Yes   0.08
  Han [@pone.0091202-Han3]                                                          3                    2004     Basal cell cancer      298      257     38           3          864    730    127    7    Yes   0.08
  Benhamou [@pone.0091202-Benhamou1]                                                1                    2004   Oral/Pharyngeal cancer   119      92      24           3          165    142    22     1    Yes   0.07
  Benhamou [@pone.0091202-Benhamou1]                                                2                    2004      Larygeal cancer       127      109     18           0          165    142    22     1    Yes   0.07
  Romanowicz-Makowska [@pone.0091202-RomanowiczMakowska3]                                                2012      Larygeal cancer       253      230     22           1          253    240    13     0    Yes   0.03
  Jiao [@pone.0091202-Jiao1]                                                        1                    2008     Pancreatic Cancer      386      340     44           2          418    368    49     1    Yes   0.06
  Jiao [@pone.0091202-Jiao1]                                                        2                    2008     Pancreatic Cancer       24      21       3           0           19     16     3     0    Yes   0.08
  Curtin [@pone.0091202-Curtin1]                                                                         2009     Colorectal cancer      1209    1014     185         10          1380   1167   204    9    Yes   0.08
  Krupa [@pone.0091202-Krupa1]                                                                           2011     Colorectal cancer      100      75      18           7          100     84    14     2    Yes   0.09
  Figueroa [@pone.0091202-Figueroa1]                                                                     2007       Bladder cancer       1138     924     208          6          1129   908    208   13    Yes   0.10
  Matullo [@pone.0091202-Matullo1]                                                                       2005       Bladder cancer       156      133     22           1          109     94    13     2    Yes   0.08
  Hung [@pone.0091202-Hung1]                                                                             2008        Lung cancer         2417    2126     281         10          3812   3324   470   18    Yes   0.07
  Zienolddiny [@pone.0091202-Zienolddiny1]                                                               2005        Lung cancer         312      203     102          7          293    246    45     2    Yes   0.08
  Bastos [@pone.0091202-Bastos1]                                                                         2009       Thyroid cancer       109      95      14           0          217    181    36     0    Yes   0.08
  Fayaz [@pone.0091202-Fayaz1]                                                                           2012       Thyroid cancer        50      43       7           0           50     45     5     0    Yes   0.05
  García-Quispes [@pone.0091202-GarciaQuispes1]                                                          2011       Thyroid cancer       397      314     79           4          477    383    90     4    Yes   0.10

\* Number °f case-control studies separately reported by articles.

^\*\*^Studies included only in the subgroup meta-analysis of ethnicity.

N: sample size in case or control group; NA: not available; HWE: Hardy--Weinberg equilibrium; MAF: minor allele frequency.

Quantitative analysis {#s3b}
---------------------

Given the fact that eligible case-control studies were mainly composed of breast cancer (N = 15) and ovarian cancer (N = 7), which brought about potential bias to the combined analysis; additionally, the considerable inherent heterogeneity among different cancer types and significant statistical heterogeneity we observed (*P~h~*\<0.001) indicated that it might not be informative to pool the data of all types of cancer into a single analysis. Therefore we performed meta-analyses respectively in groups of different cancer types, and the results were summarized in [Table 3](#pone-0091202-t003){ref-type="table"}.

10.1371/journal.pone.0091202.t003

###### Stratified analysis of the *XRCC2* Arg188His polymorphism on cancer susceptibility.

![](pone.0091202.t003){#pone-0091202-t003-3}

  Variables                                                          Dominant Model      Recessive Model    Additive Model                                       
  -------------------------------------------- ---- ------------- --------------------- ----------------- ------------------ ------------- --------------------- ---------------
  Breast                                        14   17420/17811     0.94(0.86,1.04)       0.232/0.013     1.03(0.86,1.23)    0.741/0.402     0.94(0.86,1.04)      0.251/0.004
  Caucasian[\*](#nt107){ref-type="table-fn"}    11   15192/15360     0.93(0.84,1.03)       0.158/0.012     1.02(0.86,0.22)    0.890/0.270     0.93(0.83,1.04)      0.181/0.003
                                                                                                                                                                 
  Gynecological                                                                                                                                                  
  Ovarian                                       6     3035/5554    **0.83(0.73,0.95)**     0.007/0.407     0.64(0.35,1.15)    0.136/0.601   **0.82(0.72,0.93)**    0.003/0.424
  Endometrial                                   2      447/895       0.95(0.70,1.27)       0.711/0.645     1.20(0.79,1.81)    0.399/0.553     0.98(0.73,1.30)      0.865/0.654
  Cervical                                      1      117/205     **0.43(0.21,0.87)**      0.019/NA              NA              NA        **0.43(0.21,0.87)**     0.019/NA
                                                                                                                                                                 
  Others                                                                                                                                                         
  UADT                                          3      499/583     **1.51(1.04,2.20)**     0.032/0.370     2.11(0.50,8.19)    0.309/0.508   **1.55(1.07,2.24)**    0.020/0.251
  Colorectal                                    2     1309/1480      1.10(0.90,1.35)       0.354/0.174     1.71(0.80,3.68)    0.169/0.253     1.34(0.74,2.43)      0.332/0.074
  Pancreatic                                    2      410/473       0.98(0.65,1.48)       0.926/0.768     2.17(0.20,24.05)    0.527/NA       1.00(0.67,1.51)      0.991/0.749
  Brain                                         3     528/1404       0.94(0.70,1.26)       0.673/0.529     0.78(0.19,3.22)    0.732/0.804     0.93(0.69,1.24)      0.601/0.560
  Thyroid                                       3      556/744       1.02(0.77,1.36)       0.897/0.515     1.20(0.30,4.84)     0.794/NA       1.02(0.77,1.36)      0.866/0.509
  Lung                                          2     2729/4105      1.59(0.54,4.07)      0.398/\<0.001    1.19(0.61,2.30)    0.601/0.135     1.61(0.53,4.86)     0.398/\<0.001
  Bladder                                       2     1294/1238      0.96(0.79,1.18)       0.703/0.728     0.44(0.18,1.08)    0.073/0.835     0.93(0.76,1.13)      0.469/0.831
  Skin                                          3     796/2592       0.96(0.77,1.20)       0.709/0.812     1.24(0.55,2.82)    0.605/0.993     0.97(0.78,1.21)      0.789/0.819

\*Subgroup analysis.

\*\*Number of studies included.

P: P-value of association test, *P~h~*: P-value of Q-test for heterogeneity test; NA: not available.

Breast cancer {#s3c}
-------------

A total of 17420 breast cancer cases and 17811 controls were included in the meta-analysis. As shown in [Table 3](#pone-0091202-t003){ref-type="table"}, no significant association was observed between the Arg188His polymorphism and breast cancer risk under dominant (OR = 0.94, 95%CI = 0.86--1.04, P = 0.232), recessive (OR = 1.03, 95%CI = 0.86--1.23, P = 0.741, [Fig. 2](#pone-0091202-g002){ref-type="fig"}) and additive model (OR = 0.95, 95%CI = 0.87--1.04, P = 0.298). Cumulative meta-analysis obtained no significant association as evidence accumulated by time (data not shown).

![Forest plot for the association of the *XRCC2* Arg188His polymorphism with breast cancer risk (dominant model: His/His + Arg/His vs. Arg/Arg).\
No significant association was observed between the Arg188His polymorphism and susceptibility of breast cancer.](pone.0091202.g002){#pone-0091202-g002}

There was significant heterogeneity when these breast cancer studies were combined under dominant (*P~h~* = 0.013) and additive model (*P~h~* = 0.005). Hence we carried out stratified analysis by ethnicity,but the heterogeneity did not decrease significantly among Caucasians ([Table 3](#pone-0091202-t003){ref-type="table"}). Results of meta-regression analysis showed that neither ethnicity (Coef. = 1.079, P = 0.171) nor source of controls (Coef. = 1.057, P = 0.432) contributed significantly to the heterogeneity. Sensitivity analysis found that ORs did not change significantly when excluding each single study by sequence and verified the stability of our results to some degree ([Fig.3](#pone-0091202-g003){ref-type="fig"}). It was worth mentioning that no significant heterogeneity (Dom: *P~h~* = 0.420, Add: *P~h~* = 0.712) was detected when one case-control study [@pone.0091202-Pharoah1]("Pharoah 4" in [Table 1](#pone-0091202-t001){ref-type="table"}) from USA was excluded, which implied that this study might be the origin of the heterogeneity under dominant and additive model.

![Sensitivity analysis on the association between the *XRCC2* Arg188His polymorphism and susceptibility of breast cancer (dominant model: Arg/His+His/His vs. Arg/Arg).\
No statistically different results were obtained by excluding every single study in sequence.](pone.0091202.g003){#pone-0091202-g003}

The Begg\'s funnel plot of dominant model seemed symmetrical ([Fig. 4](#pone-0091202-g004){ref-type="fig"}), and Egger\'s test provided statistical evidence which identified the absence of publication bias (Dom: t = 0.41, p = 0.690). Results of recessive and additive model showed no significant publication bias either (data not shown).

![Begg\'s funnel plot on publication bias for eligible studies that focused on the association of the *XRCC2* Arg188His polymorphism with the breast cancer susceptibility (dominant model: Arg/His+His/His vs. Arg/Arg).\
The funnel plot seemed symmetrical, indicating no publication bias.](pone.0091202.g004){#pone-0091202-g004}

Gynecological cancer {#s3d}
--------------------

Considering 6 of the 10 studies investigated ovarian cancer, and it might generate misleading results for the combined analysis of all types of gynecological cancer, we conducted meta-analysis separately for each type of gynecological cancer. We observed that variant allele carriers (His/His + Arg/His) had significantly lower risk for developing ovarian cancer (OR = 0.83, 95%CI = 0.73--0.95, P = 0.007, [Fig.5](#pone-0091202-g005){ref-type="fig"}). However, no significant association was detected between this polymorphism and endometrial cancer ([Fig.5](#pone-0091202-g005){ref-type="fig"}). Only one study focusing on cervical cancer reported significant association between the Arg188His polymorphism and decreased susceptibility. Moreover, we did not detect any significant heterogeneity among the eligible studies in each comparison (details in [Table 3](#pone-0091202-t003){ref-type="table"}). For ovarian cancer, the Begg\'s funnel plot and Egger\'s test indicated no significant publication bias under the three different genetic models (data not shown). The result of sensitivity analysis for ovarian cancer group found the ORs did not change significantly when every single study were excluded.

![Forest plot for the subgroup analysis of gynecological cancer (dominant model: Arg/His+His/His vs. Arg/Arg).\
Significant association was detected between the *XRCC2* Arg188His polymorphism and decreased risk for ovarian cancer and cervical cancer.](pone.0091202.g005){#pone-0091202-g005}

Other Cancers {#s3e}
-------------

Relatively small number of studies covered other types of cancers. In our study, the UADT cancer consisted of oral, pharyngeal and laryngeal cancer. Significant association was observed between the Arg188His polymorphism and increased susceptibility of UADT cancer (Dom: OR = 1.51, 95%CI = 1.04--2.20, P = 0.032, [Fig.6](#pone-0091202-g006){ref-type="fig"}; Add: OR = 1.51, 95%CI = 1.06--2.16, P = 0.023), and no significant heterogeneity was found in any genetic model ([Table 3](#pone-0091202-t003){ref-type="table"}). As for digestive system cancers, we detected no significant association between this polymorphism and either pancreatic or colorectal cancer. In addition, current evidence did not suggest that the Arg188His polymorphism was associated with risk for brain, skin, thyroid, bladder and lung cancer (details in [Table 3](#pone-0091202-t003){ref-type="table"}).

![Forest plot for the association between the *XRCC2* Arg188His polymorphism and UADT cancer risk (dominant model: Arg/His+ His/His vs. Arg/Arg).\
Significant association was observed between this polymorphism and increased risk for UADT cancer.](pone.0091202.g006){#pone-0091202-g006}

Discussion {#s4}
==========

As research moved along, the genomic landscape of cancer has been gradually brought into light, and an increasing number of vital genes shared by various cancers, *XRCC2* for example, have been revealed in recent years. The *XRCC2* Arg188His polymorphism was widely reported to be associated with susceptibility of a wide range of cancers. However, results remained conflicting and a single study might be limited due to a relatively small sample size. Moreover, no conclusive study so far has reported a result which covered all available cancer types. Based on all published literature, we performed this meta-analysis to identify the association of the Arg188His polymorphism with cancer susceptibility.

Our study, which derived an asymmetrical distribution of different cancer types, contained 15 studies for breast cancer and 7 for ovarian cancer, generating potential bias to the combined analysis of all cancer types. Moreover, considerable inherent heterogeneity existed among different cancer types, which was confirmed by significant statistical heterogeneity we obtained. Current evidence indicated that the *XRCC2* Arg188His polymorphism might play various roles in different cancer types. Thus it could be of little value to combine all data of different cancer types into a single analysis.

According to our meta-analysis of breast cancer, we observed no significant association between this polymorphism and susceptibility of breast cancer, which accorded with the previous meta-analysis. However, in the previous study, Yu et al [@pone.0091202-Yu1]reported their result with unexplained significant heterogeneity (*Ph* = 0.014). Furthermore, studies inconsistent with HWE were included in the meta-analysis which might result in potential bias. Limited by factors above, results of previous study should be interpreted with caution. In our study, we detected no significant heterogeneity when one case-control("Pharoah 4" in [Table 1](#pone-0091202-t001){ref-type="table"}) study was [@pone.0091202-Pharoah1] excluded, which implied the probability of the removed study being the origin of heterogeneity. We noted that in this case-control study from USA, buccal cells as DNA samples were collected by mail from participants ,which could brought in possible inaccuracy. However, insufficient information was provided for further identification of the heterogenous factor of this study. Additionally, cumulative meta-analysis suggested that no significant association was observed as evidence accumulated by time. Theoretically, genetic variants in the *XRCC2* gene could change the regular function of this gene, disturb the DNA repair and increase cancer risk. However, a previous study [@pone.0091202-Danoy1] has identified that the variant allele of this polymorphism could increase resistance to the DNA damage induced by cisplatin, which enlightened protective function of this polymorphism under certain conditions. This finding is to some degree consistent with our paradoxical result of the non-significant association between this polymorphism and breast cancer risk. Future studies should aim at the response of variant allele carriers to specific DNA damage agents of breast cancer.

As for gynecological cancer, we found that variant allele carriers had significantly lower risk for developing ovarian cancer. Our results suggested a protective role of the Arg188His polymorphism, which was apparently paradoxical to the presumable hypothesis. As mentioned above, the previous study [@pone.0091202-Danoy1] indicated that the Arg188His polymorphism might response differently to various damaging agents. It is notable that in one of the studies included in our meta-analysis, Pérez et al [@pone.0091202-Perez1] adopted HPV adjusted ORs and found the variant allele (A allele) was associated with reduced risk for cervical cancer, which derived a hypothesis that this polymorphism might play a different role in HPV-induced DNA damage. However, our paradoxical findings of gynecological cancer should be interpreted with caution, because only a small number of studies investigating ovarian, endometrial and cervical cancer were finally included in our meta-analysis. A large number of studies with specific damaging factors in consideration should be accumulated to provide further estimate on the association between this polymorphism and gynecological cancer risk.

In our study, we detected significant association between the Arg188His polymorphism and increased UADT cancer, but the result was limited by the small sample size. Considerable caution should be taken into account because only 3 studies were included. Meanwhile, biological heterogeneity is likely to exist among oral cavity, pharyngeal and laryngeal cancer. A few studies investigated other cancer types (brain, skin, thyroid, pancreatic, colorectal cancer); however, we found no significant results in these subgroups. More studies are required to achieve conclusive results for these cancer types and future work should cover cancers that have not been investigated such as gastric, esophageal and hematological cancer.

To our knowledge, this is the most comprehensive meta-analysis which has first investigated the association between the *XRCC2* Arg188His polymorphism and susceptibility of all available cancer types. However, several limitations should be taken into consideration when explaining the results: (1) we only included the studies from selected databases, thus other relevant records might be left out; (2) the number of studies include was relatively small for some cancer types. For example, only one study investigated cervical cancer; (3) due to insufficient information, stratified analysis cannot be conducted by age, sex, treatment, drinking status, exposure to radiation and other factors;(4) lacking of necessary data limited further assessment for gene-gene and loci-loci interaction; (5) as only Caucasian and African American were involved in the pooled analysis, the results might not suit for other ethnicities.

In conclusion, our meta-analysis found that the impact of the *XRCC2* Arg188His polymorphism on susceptibility of different cancers might be diverse. Current evidence did not suggest this polymorphism was directly associated with breast cancer risk. However, we observed that the variant allele carriers might have significantly lower risk for developing gynecological cancer, especially ovarian cancer. Our results should be explained with some caution and be re-evaluated in the future when more studies with larger sample size are conducted.
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